| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for Cell Therapeutics, Inc. > News item |
Cell Therapeutics' CPOP trial shows pixantrone offers improved rates of remission
By Elaine Rigoli
Tampa, Fla., March 22 - Cell Therapeutics, Inc. released preliminary results of a phase 1/2 clinical trial of pixantrone in 64 patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) who had previously failed one or two prior chemotherapy regimens, including the CHOP regimen.
The CHOP regimen includes cyclophosphamide, vincristine, prednisone and doxorubicin, whereas the CPOP regimen includes pixantrone, cyclophosphamide, vincristine and prednisone.
All patients had received prior doxorubicin therapy and as such were at risk for developing severe cardiac toxicity with additional anthracycline therapy, according to a company news release.
The CPOP regimen was highly effective, with complete response/unconfirmed complete response rates of 41% (14 of 34 patients) and 43% (13 of 30 patients) and overall response rates of 71% (24 of 34 patients) and 77% (23 of 30 patients) in the phase 1 and 2 component of the study, respectively.
There was one case of congestive heart failure reported, which was felt by the investigator to be related to the patient's underlying cardiac disease, the release said.
"These data suggest that in the relapsed setting, substituting pixantrone for doxorubicin can offer patients a high probability of achieving a complete remission not available with standard chemotherapy regimens and underscores the rationale for studying the CPOP regimen versus the CHOP regimen in first-line treatment of aggressive NHL," said James A. Bianco, president and chief executive officer, in a statement.
Based in Seattle, Cell Therapeutics is a biopharmaceutical company that develops oncology products aimed at making cancer more treatable.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.